WebSep 6, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to … WebMar 23, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to …
SEC Filings Dyne Therapeutics, Inc.
WebJan 20, 2024 · WALTHAM, Mass., Jan. 20, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the pricing of an underwritten public offering of 6,000,000 shares of its … WebDoing Business As: Dyne Therapeutics Company Description: Key Principal: Joshua Brumm See more contacts Industry: Pharmaceutical preparations Printer Friendly View Address: 1560 Trapelo Rd Waltham, MA, 02451-7306 United States Phone: Website: www.dyne-tx.com Employees (this site): Actual Employees (all sites): Actual hilger face clinic
Dyne Therapeutics launches with $50 million for …
WebOct 31, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically … WebSep 13, 2024 · Dyne Therapeutics had filed proposed terms for a $175 million U.S. IPO. The firm is advancing treatments for various muscle diseases. DYN has yet to enter Phase 1 safety trials, so the IPO may... WebAspects of the disclosure relate to molecular payloads that modulate the expression or activity of genes involved in muscle growth and maintenance (e.g., MSTN, INHBA, and/or ACVR1 hilger face center edina